Chemotherapy

Chartwell Enhances IV Preparations with Omnicell® IVX Workflow

Retrieved on: 
Wednesday, July 7, 2021
Software, Supply chain management, Pharmaceutical, Oncology, Specialty, Technology, Hospitals, Fitness & Nutrition, Retail, Biotechnology, Practice Management, Health, Health, Pharmacy, Doctor of Pharmacy, Pharmacist, Chemotherapy, Compounding, Barcode, Omnicell, Chartwell Pennsylvania, LP, CarepathRx, Omnicell, CHARTWELL PENNSYLVANIA, LP, CAREPATHRX, OMNICELL

Chartwell Pennsylvania, LP , the nations leading health-system based provider of home infusion, specialty pharmacy, and enteral nutrition, has partnered with Omnicell to install their IVX Workflow sterile compounding technology to manage chemotherapy drug product preparations.

Key Points: 
  • Chartwell Pennsylvania, LP , the nations leading health-system based provider of home infusion, specialty pharmacy, and enteral nutrition, has partnered with Omnicell to install their IVX Workflow sterile compounding technology to manage chemotherapy drug product preparations.
  • Developing new and innovative competencies with this type of technology further enhances CarepathRxs leadership role in the health-system direct home infusion treatment space.
  • The use of Omnicells IVX Workflow allows Chartwell technicians to implement a step-by-step preparation of chemotherapy that employs gravimetric verification and barcode-scanning.
  • In addition to barcode scanning and gravimetrics, Chartwell implemented automated photography to give our pharmacists the ability to review each step throughout the IV preparation, said Kyra Wivagg, PharmD, Manager of Pharmacy Operations at Chartwell.

PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors

Retrieved on: 
Wednesday, July 7, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medicine, Cancer treatments, Virotherapy, Cancer immunotherapy, Antineoplastic drugs, Immunotherapy, Chemotherapy, Cancer, Treatment of cancer

In addition, PureTech plans to investigate LYT-200 as a single agent and in combination with other anti-cancer treatments, including chemotherapy and other immunotherapies.

Key Points: 
  • In addition, PureTech plans to investigate LYT-200 as a single agent and in combination with other anti-cancer treatments, including chemotherapy and other immunotherapies.
  • Tislelizumab has been approved in China for four solid tumor indications and regulatory decisions are pending for two additional indications.
  • We look forward to evaluating whether LYT-200 in combination with BeiGenes tislelizumab can improve outcomes for patients with metastatic solid tumors.
  • Under the terms of the agreement, PureTech will maintain control of the LYT-200 program, including global R&D and commercial rights.

Global Erythropoietin Drugs Market to 2027 by Drug Class, Product, Application, Regional Outlook - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Health, Pharmaceutical, Clinical medicine, Medicine, Branches of biology, Growth factors, Cytokines, Erythropoietin, Chemotherapy, Abbreviated New Drug Application

The "Global Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Erythropoietin Drugs Market By Drug Class, By Product, By Application, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global Erythropoietin Drugs Market size is expected to reach $20.2 billion by 2027, rising at a market growth of 11.8% CAGR.
  • The post-abbreviated new drug application (ANDA) is getting approvals and there is a high success rate of erythropoietin drugs in chemotherapy-induced anaemia.
  • Therefore, the impact of the COVID-19 pandemic is likely to have a positive impact on the erythropoietin drug market.

Luvme Hair Supporting E-Beauty's Wig Donation Program to Empower Women Undergoing Chemotherapy

Retrieved on: 
Wednesday, July 7, 2021
Organ systems, Clinical medicine, Medicine, Cancer treatments, Human hair, Hairdressing, Hair loss, Chemotherapy, Wig, Hair

NEW YORK, July 6, 2021 /PRNewswire/ -- Luvme Hair, a luxury human hair wig brand, has focused on women's health issues for many years.

Key Points: 
  • NEW YORK, July 6, 2021 /PRNewswire/ -- Luvme Hair, a luxury human hair wig brand, has focused on women's health issues for many years.
  • They kicked off their wig donation drive to benefit the women undergoing chemotherapy treatments.
  • According to pharmacy times, approximately 65% of individuals undergoing chemotherapy will experience chemotherapy-induced hair loss.
  • Forty-seven percent of female cancer patients consider hair loss to be the most traumatic aspect of chemotherapy, with 8% of them stating they would decline treatment for fear of hair loss.To support and empower our global community, Luvme Hair plans to help these women in need overcome their hair loss due to chemotherapy through their wig donations program.

Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021

Retrieved on: 
Tuesday, July 6, 2021
Clinical medicine, Medicine, Antineoplastic drugs, Cancer, Biotechnology, PLK1, Targeted therapy, Biomarker, Oncology, Chemotherapy

A replay of the fireside chat will be available by visiting the " Events " section of the Cardiff Oncology website after its conclusion and will be archived on the Company website for 30 days.

Key Points: 
  • A replay of the fireside chat will be available by visiting the " Events " section of the Cardiff Oncology website after its conclusion and will be archived on the Company website for 30 days.
  • Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.
  • We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.
  • Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment.

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia

Retrieved on: 
Tuesday, July 6, 2021
Chemical compounds, Organic compounds, Clinical medicine, Orphan drugs, Antineoplastic drugs, Breakthrough therapy, Benzamides, Chloroarenes, Venetoclax, Azacitidine, 7+3, Chemotherapy

Preclinical studies have shown that TTI-622 exhibits anti-tumor activity against AML cells as a monotherapy that is enhanced when combined with azacitidine or venetoclax.

Key Points: 
  • Preclinical studies have shown that TTI-622 exhibits anti-tumor activity against AML cells as a monotherapy that is enhanced when combined with azacitidine or venetoclax.
  • The dosing of this patient marks the second combination cohort that has been initiated with TTI-622, commented Dr. Ingmar Bruns, Trilliums Chief Medical Officer.
  • The combination of TTI-622 and azacitidine and venetoclax is being assessed as part of the ongoing, open-label study (NCT03530683).
  • Significant unmet medical need remains for elderly AML patients or those who are unfit for intensive chemotherapy, added Dr. Bruns.

Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Thursday, July 1, 2021
Clinical medicine, Cancer, Medicine, Antineoplastic drugs, Cancer treatments, Lung cancer, Oncology, Antifolates, Pemetrexed, Targeted therapy, Chemotherapy, Treatment of lung cancer

Aileron plans to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors in this Phase 1b trial.

Key Points: 
  • Aileron plans to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors in this Phase 1b trial.
  • When devising treatment strategies for todays cancer patients, the use of targeted therapies is certainly preferred when possible.
  • In cancer cells, the cell cycle is unchecked, which leads to uncontrolled cell proliferation, a hallmark of cancer.
  • Aileron is a clinical stage chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients.

FDA Approves Component of Treatment Regimen for Most Common Childhood Cancer

Retrieved on: 
Wednesday, June 30, 2021
Clinical medicine, Medicine, Antineoplastic drugs, Cancer, Cancer treatments, Asparaginase, Chemotherapy, Leukemia, 7+3

"Today's approval may provide a consistently sourced alternative to a pivotal component of potentially curative therapy for children and adults with this type of leukemia."

Key Points: 
  • "Today's approval may provide a consistently sourced alternative to a pivotal component of potentially curative therapy for children and adults with this type of leukemia."
  • It is the most common type of childhood cancer.
  • One component of the chemotherapy regimen is an enzyme called asparaginase that kills cancer cells by depriving them of substances needed to survive.
  • The most common side effects of Rylaze include hypersensitivity reactions, pancreatic toxicity, blood clots, hemorrhage and liver toxicity.

CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study

Retrieved on: 
Monday, June 28, 2021
Oncology, Health, Infectious diseases, General Health, Clinical trials, Pharmaceutical, Biotechnology, Cancer, Clinical medicine, Medicine, Cancer treatments, Health effects of tobacco, Otorhinolaryngology, Head and neck cancer, Chemotherapy, Radiation therapy, 7+3, Cyclophosphamide, Multikine, Head and Neck Cancer, CEL-SCI Corporation, MULTIKINE, HEAD AND NECK CANCER, CEL-SCI CORPORATION

This group represents about 155,000 patients worldwide, or about 40% of all advanced primary head and neck cancer cases annually.

Key Points: 
  • This group represents about 155,000 patients worldwide, or about 40% of all advanced primary head and neck cancer cases annually.
  • The chemotherapy, cisplatin, was given intravenously and may have negated the survival benefit imparted by Multikine immunotherapy in these patients.
  • The two main comparator arms of the study were: the Multikine treatment regimen (Multikine plus CIZ: cyclophosphamide; indomethacin; zinc-multivitamins) plus SOC vs. SOC alone.
  • In each of these comparator arms, patients were determined by pathology following surgery to receive radiotherapy only or concurrent radio-chemotherapy.

Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice

Retrieved on: 
Monday, June 28, 2021
Cancer, Clinical medicine, Medicine, Oncology, Colorectal cancer, Chemotherapy

The study objective was to evaluate the potential efficacy of the RCC-33 drug candidate as a systemic treatment for colorectal cancer when administered orally.

Key Points: 
  • The study objective was to evaluate the potential efficacy of the RCC-33 drug candidate as a systemic treatment for colorectal cancer when administered orally.
  • The announcement comes following previously released in-vivo study results demonstrating a 33% reduction in tumor volume in mice treated with RCC-33 using intraperitoneal (IP) injection.
  • Gabriel Yariv, Cannabics Pharmaceuticals President & COO said: "Our first POC study in mice demonstrated that RCC-33 has potential anti-tumor effect on colorectal cancer.
  • For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.